Risk factors of new onset diabetes mellitus and dyslipidemia -and effects

RISK FACTORS OF CARDIOVASCULAR DISEASES
The leading causes of death in patients who died with a functioning allograft are cardiovascular diseases [1] , which account for almost 40 percent of all deaths in this population. Renal transplantation (Tx) is the treatment modality of choice for virtually all suitable candidates with end-stage renal disease. Studies suggest that the survival advantage of transplantation may be largely attributed to the reduce in cardiovascular diseases (CVD).
Obesity, impaired fasting glucose (IFG) or diabetes mellitus, hypertriglyceridemia or reduced high-density lipoprotein (HDL) level, hypertension, immunosuppressive (IS) therapy, cyclosporine-A (CsA)] and tacrolimus (Tac) and smoking are high-risk factors for the development of cardiovascular diseases [2, 3, 4] . The mechanism of action of calcineurin inhibitors (cycylosporine-A and tacrolimus) is that they block one limb of the activation, the calcineurin pathway ( Figure 1 .) Figure 1 . One pathway leads to activation of calcineurin and the other to activation of mitogen-activated protein kinases (MAPKs). The end result is IL-2 gene transcription.
Cyclosporine-A and tacrolimus block one limb of the activation, the calcineurin pathway. Tissue sampling: Before the transplantation, a histological sample was taken from each
kidney not yet implanted ("zero biopsy"). We performed a protocol biopsy 3 months, 1 year and 3 years after transplantation. We studied those patients whose "zero biopsy" was intact, and in whom we could perform protocol biopsy 1 year after the transplantation.
The ultrasound-guided protocol biopsy was performed (with the patient's prior consent)
after the one-year fasting laboratory test. 16-G Tru-Cut needles and a biopsy gun were used to obtain the tissue cylinders. 
ACUTE CELLULAR REJECTION (ACR)
Types ( not undergone primary cadaver kidney transplantation, had been diagnosed with diabetes and dyslipidemia before the transplantation, had shown a hypertensive kidney on their "zero biopsy" or had not consented to the protocol biopsy were excluded from the study.
The control group was formed by patients with normal glucose and lipid metabolism.
We enlisted the patients into 4 groups (N, IFG, IGT, and PTDM) in Study I and into 4 groups (N, NODM, NODL, NODM+NODL) in Study II. In Study II the NODM group involved other (IFG, IGT) abnormal glucose metabolism.
IMMUNOSUPPRESSIVE DRUGS ADMINISTERED 1 YEAR AFTER TRANSPLANTATION
The initial daily dose of Tac was 0.20 mg/kg in two portions, and then the target blood level was 10-15 ng/mL for 6 weeks and 5-10 ng/mL after week 6.
The initial dose of CsA was 8-10 mg/kg daily, in two portions, and then the target blood level was 1,300-1,600 ng/mL in month 1, 900-1300 ng/mL in months 2 and 3, 750-950 ng/mL in months 4 to 6 and 700 ng/mL afterwards (blood levels were determined two hours after administration).
The initial dose of sirolimus (SRL) was 0.1 mg/kg once daily; the target blood level was 10-15 ng/mL for 6 weeks and then 5-10 ng/mL.
In the case of everolimus (EVR), the initial dose was 0.02 mg/kg twice daily, and then the target level was 3-8 ng/mL. 500 mg steroid (S) was administered intravenously on day 0 in the operating room, immediately before restoring blood flow to the graft; 125 mg was administered intravenously on day 1, 32 mg orally on day 2, 24 mg orally on day 3, 16 mg orally on days 4 to 28, 12 mg orally during month 2, 8 mg orally during month 3, and 4 mg orally during months 4 to 6. The dose was further decreased in problem-free cases.
The daily dose of mycophenolate mofetil (MMF) was 2 g in two portions and was reduced by 50 or 75% in the event of gastrointestinal symptoms or leucopenia.
mg/kg antithymocyte globulin (ATG) was administered for 7 to 21 days.
Basiliximab was given on day zero within 2 hours prior to the operation 20 mg i.v. and 20 mg i.v. on day 4.
For the treatment of ACR, steroid in a daily dose of 500 mg was administered intravenously for 3 days, followed by 250 mg per day intravenously for 2 days.
RISK FACTORS
We examined the donor and the initial and the one-year after transplantation recipient data Table 2) . We examined the effect of lipids on glucose metabolism. 
HISTOPATHOLOGICAL EXAMINATION OF THE ALLOGRAFT
Before the transplantation, a histological sample was taken from each kidney not yet implanted ("zero hour" biopsy). We studied the one-year protocol biopsies of those patients who had a normal histology result of the zero biopsy.
STATISTICAL ANALYSIS
For the comparison of the mean values, t-test and one-way analysis of variance were used, as well as the Mann-Whitney and Kruskal-Wallis tests in cases of non-normality. The normal distribution of samples was tested by using the Kolmogorov-Smirnov test. Categorical data were analyzed by using chi-square and Fisher's exact tests. Temporal changes in renal function parameters were compared by using repeated measures of the analysis of variance (ANOVA). The multivariable dependence of NODM and NODL on both categorical and continuous data was analyzed by using logistic regression. SPSS version 15.0 (© 2007 SPSS Inc.) was used for statistical analys.
RESULTS
STUDY I -POST-TRANSPLANT DIABETES MELLITUS
RISK FACTORS OF THE PTDM
Of the initial and one-year after transplantation data relating to the donors and the recipients, Table 3) .
N (n=115)
Mean ± SD
IFG (n=8)
IGT (n=6)
Mean ± SD Table 4 . Incidence of diabetes mellitus and impaired glucose tolerance in patients treated with cyclosporine-A or tacrolimus.* p < 0.004 indicated significant difference between the cyclosporine-A and tacrolius groups.
PTDM (n=25)
N -normal; IFG -impaired fasting glucose; IGT -impaired glucose tolerance; PTDM -posttransplant diabetes mellitus; CsA-cycylosporine -A; Tac-tacrolimus
In the case of combined CsA-S treatment, 10.4% of the patients developed diabetes, and there was a significant difference if we compared it to the group of patients taking CsA without steroids 4.5% (p = 0.044). The incidence of newly developed diabetes among patients on the Tac-S combination was 27.7%; compared to the incidence rate in patients receiving steroidfree immunosuppression 21.1%, which was not significantly different (p = 0.846). No significant difference, in regard to the development of diabetes, was found between the normal and the PTDM groups in case of the combinations of MMF and Tac (p = 0.76), SRL
and Tac (p = 0.53), and EVR and Tac (p = 0.43).
FUNCTIONAL CHANGES OF THE ALLOGRAFT
Studying the functional changes of the allograft one year after the transplantation, we found that the serum creatinine value was 151.56±44.38 μmol/L in normal patients and Table 5 ).
year after Tx
Mean ± SD 
NODM-new onset diabetes mellitus; NODL-new onset dyslipidemia; OR-odds ratio; BMI-body mass index
When assessing the effect of CNIs (and, more specifically CsA and Tac) on glucose and lipid metabolisms, we found that those taking Tac developed diabetes significantly more frequently than those taking cyclosporine-A (p = 0.005), whereas the development of dyslipidemia was significantly more frequent in those taking CsA than in those taking Tac (p = 0.001) ( CNI-calcineurin inhibitor; CsA-cyclosporine-A; Tac-tacrolimus; TG-triglyceride; TCtotal cholesterol; LDL-low-density lipoprotein; HDL-high-density lipoprotein
FUNCTIONAL CHANGES OF THE ALLOGRAFT
In regard to the function of the allograft, we found that there was significant difference in the serum creatinine level between the NODM+NODL group and the N group (p = 0.02) one year after the transplantation. The difference was not significant when comparing the NODM group and the NODL group with the N group. A similar result was obtained when assessing eGFR CG : the difference between NODM+NODL patients and N patients was significant (p=0.004) ( Table 11 . Serum creatinine and eGFR CG one year after transplantation in the different glucose and lipid metabolisms groups.
N-normal; NODM-new onset diabetes mellitus; NODL-new onset dyslipidemia;
eGFR CG -estimated glomerular filtration rate Cockroft-Gault
HISTOPATHOLOGICAL CHANGES OF THE ALLOGRAFT
When studying the morphological changes of the kidney, there was significant difference between the N and the NODM groups in ACR (6% vs. 25%, p = 0.004) and IF/TA (4% vs.
55%, p = 0.0002). In case of IF/TA, the difference between N and NODL patients was significant (4% vs. 36%, p = 0.003). Between the N and the NODM+NODL groups, the difference in IF/TA (4% vs. 41%, p = 0.0001) and ACR (6% vs. 24%, p = 0.03) was proved to be significant (Table 12, Figure 5 ). In our study, the incidence of new-onset diabetes mellitus was 17%, whereas that of newonset dyslipidemia was 22% in the patient population. We assessed the effects of NODM and NODL on each other, and we found that NODM, total cholesterol level and triglyceride level mutually affect the development of each other. In the studies by Valderhang et al. [11] , the incidence of diabetes has been 17% and 14%, respectively.
Diabetic and dyslipidemic patients are continouosly at elevated risk for developing CVD and other diabetic and dyslipidemic complications. This is also true for those developing newonset diabetes and dyslipidemia after transplantation, who very rapidly develop comparable risks for CVD and death. Kamar et al. [12] and Schiel et al. [13] have found similar results, namely that the risk factors of NODM include not only the immunosuppressive agents but also family history and age, body weight and BMI of the recipient, and these play at least the same importance in the development of diabetes [13, 14, 15, 16] . Immunosuppressive therapy, the age of the recipient and body mass index had a significant effect on the development of NODM and NODL. Other clinical trials have also found these factors to be significant [17, 18, 19] .
Obesity is a potentially detrimental condition due to its associated comorbid conditions including hyperinsulinemia and insulin resistance, diabetes mellitus and dyslipidemia.
Obesity defined as BMI ≥ 30kg/m 2 has a reported prevalence of 9.5-29% on transplantation [19] . Studies reporting on renal transplant recipients have shown that high BMI at transplant is a significant independent predictor of congestive heart failure and atrial fibrillation. In two large historic cohort studies using the United Renal Data System Registry database, Abbott et al. [18] and Lentine et al. [17] When studying the effects of the immunosuppressive agents tacrolimus and cyclosporine-A on glucose and lipid metabolisms, the development of diabetes has been found to be significantly more frequent in those taking tacrolimus (24% vs. 12%), whereas those taking cyclosporine-A developed dyslipidemia significantly more frequently (30% vs. 16%) [8, 21] .
In the PTDM group of Study I, patients taking tacrolimus developed diabetes more frequently (Tac vs. CsA: 26.8% vs. 8.6%). In a study by Vincenti et al., the incidence of diabetes has been 33.6% with Tac and 26% with CsA treatment [20] , whereas Heisel et al. have reported that the incidence of NODM is 16.5% in case of tacrolimus and 9.8% in case of cyclosporine-A [21] . When comparing cyclosporine-A and tacrolimus therapies, the differences in triglyceride and total cholesterol have been significant (p = 0.004 and p = 0.001, respectively), but no significant difference has been found in HDL and LDL values. Badiou et al. have had a similar result: triglyceride and total cholesterol levels are significantly higher in patients taking cyclosporine-A than in those receiving tacrolimus therapy (6.14±1.37 vs.
5.28±1.32 mmol/L and 28% vs. 8%, respectively) [8] . Mycophenolate mofetil and sirolimus have not affected the development of diabetes [22] . In the PTDM group of Study I, patients taking tacrolimus developed diabetes more frequently (Tac vs. CsA; 26.8% vs. 8.6%) [24, 25, 26, 27] . We found a significant difference between combined CsA-S treatment and Sfree CsA treatment in regard to the development of diabetes, whereas the difference was not significant between combined Tac-S treatment and S-free Tac treatment [28] . Greater steroid exposure was associated with the development of glucose metabolism abnormalities in the CsA-group but not in the tacrolimus-treated patients. It may suggest that steroid played a major role in the development of diabetes in the CsA-treated patients. With tacrolimus, a reduction in steroid dose did not appear to affect the glycemic status, probably because tacrolimus had an impact on insulin secretion [24] .
Treatments of diabetes mellitus
Lifestyle modification fails to achieve adequate glycemic control, therefore, medical intervention is recommended. Orally administered agents can be used either alone or in combination with other oral agents or insulin. Although oral hypoglycemic agents may be effective in many patients with corticosteroids or CsA-or Tac-induced NODM, insulin therapy may ultimately be necessary in up to 25% of patients, particularly in the early posttransplant period.
Metformin is the preferred agent for overweight patients; its use should be avoided with impaired allograft function due to the possibility of lactic acidosis. Care should also be taken when sulfonylurea derivatives are prescribed to patients with impaired allograft function or to elderly patients due to increased risk of hypoglycemia. "Non-sulfonylureatic" meglitinides are insulin secretagogues with a mechanism of action similar to that of sulfonylureas.
Nonetheless, they have a more rapid onset and shorter duration of action and seemingly lower risks for hypoglycemia and lower amount of weight gain [29, 30] . Thiazolidinedione derivatives are insulin sensitizers that may allow for a reduction in insulin requirement. The incidence of peripheral edema in increased when thiazolidinedione derivatives are used in combination with insulin [28] . When added to sulfonylureas, thiazolidinedione derivatives and/or metformin, it results in additional lowering of HbA 1C by approximately 0.5-1%.
Treatments of the dyslipidemia
Besides the well-established efficacy and safety of the use of statins in transplant recipients, clinicians should remain vigilant to the potential drug to drug interactions in transplant patients who often require multiple medications. The use of statins in the presence of calcineurin inhibitors, particularly cyclosporine-A, often results in a severalfold increase in statin blood level and an increased risk for myopathy and rhabdomyolysis [29] . In addition to their lipid lowering effect, statins may offer protection against CVD via their antiproliferative and anti-inflammatory properties and ability to reduce circulating endothelin-1, C-reactive protein levels, systolic and diastolic blood pressure and pulse. Other classes of lipid lowering agents include fibric acid derivatives, nicotinic acid and ezetimibe [30] Ezetimibe and statin combination therapy can significantly improve cholesterol control due to their complementary mechanisms of action [31] . No significant drug to drug interaction between ezetimibe and calcineurin inhibitor has been reported.
Functional changes
One year after transplantation, no significant difference could be shown between diabetic patients and normal patients in regard to their serum creatinine and eGFR levels. The difference in regard to the allograft function was significant only between the NODM+NODL group and the N group, which proves that if both conditions are present, it may lead to the functional impairment of the graft even one year after transplantation. When comparing the first and the fifth post-transplantation years, we found a significant difference between the two groups (N-PTDM) in the serum creatinine but not in the eGFR CG and eGFR MDRD values [19] .
We reached a different result in regard to the histopathological changes of the kidney. In the one-year protocol biopsies, we observed that the difference between the NODL and the N groups was significant only in regard to IF/TA, whereas both IF/TA and ACR differed significantly in the NODM and the NODM+NODL groups, when compared to the normal group [30, 31, 32, 33, 34] . In the study of Arif et al., diabetic and normal patients have differed significantly in IF/TA (p < 0.001) [35] .
Our own clinical study proved that one year after transplantation the allograft function had already been impaired if both medical conditions (NODM and NODL) were present;
however, in regard to morphology, a single condition (NODM or NODL) was sufficient to lead to histological changes in the kidney. One year after kidney transplantation diabetic nephropathy (especially mesangial matrix increase and arteriola hyalinosis) did not develop, however, permanent hyperglycemia might result in morphological changes of the allograft. In IF/TA, hyperglycemia led to fibrogenesis by decreasing the number of functioning nephrons.
It may be confirmed that the disruption of glucose and lipid homeostases severely damages the allograft, and this, without timely recognition and treatment, may not only lead to irreversible damages in the allograft, but it may increase the cardiovascular risks as well. Protocol biopsy may make it possible to recognize the harmful effects of NODM and NODL on the graft earlier; thus, with the timely initiation of treatment, the graft may be preserved in the long term, and the risks of diabetes may be decreased. With the help of the protocol biopsy, an individually tailored immunosuppressive therapy can be set up for each patient.
The immunosuppressive therapy and the intensity of care provided to transplant recipients should be tailored to their needs, but in general, it is recommended that after a gradual reduction in the frequency of visits from 2 times per month during the fourth month to 1 occassion per month in the 6th month, this monthly schedule should be maintained until the end of the first year. In the next year, visits should be organized every 1 to 2 months and thereafter every 3 to 4 months as long as the transplant in functioning. Follow-up can take place at the clinic of the transplantation center, with a community nephrologist and a diabetologist experienced in the care of transplant recipients.
Considering the aforementioned findings, we might not only be able to preserve allograft function but also increase the survival of the patients.  The prevalence of diabetes mellitus was 17%, whereas that of dyslipidemia was 22% one year after transplantation in our study. The development of diabetes and dyslipidemia was significantly influenced by the age and body mass index of the recipient and the immunosuppressant therapy.
SUMMERY AND NEW FINDINGS
 The prevalence of diabetes was significantly increased in patients taking tacrolimus, and that of dyslipidemia was significantly increased in patients taking cyclosporine-A. The triglyceride and total cholesterol levels of patients taking cycylosporine-A and tacrolimus were significantly different.
 One year after kidney transplantation, measuring the function of the allografts did not reveal any difference between patients having diabetes or dyslipidemia and patients with normal glucose and lipid metabolisms. However, this difference was significant if a patient had both factors (diabetes and dyslipidemia).
 Analyzing glucose metabolism, serum creatinine level was significantly different in the post-transplantation diabetes mellitus group one and five years after kidney transplantation.
 Evaluating the morphology of the allograft showed that one year after transplantation, there were significant differences in interstitial fibrosis/tubular atrophy and acute cellular rejection in normal patients vs. diabetic patients and normal patients vs. patients having diabetes&dyslipidemia. 
